Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
| Autor: | Moehler, M., Maderer, A., Schimanski, C., Kanzler, S., Denzer, U., Kolligs, F.T., Ebert, M.P., Distelrath, A., Geissler, M., Trojan, J., Schütz, M., Berie, L., Sauvigny, C., Lammert, F., Lohse, A., Dollinger, M.M., Lindig, U., Duerr, E.M., Lubomierski, N., Zimmermann, S., Wachtlin, D., Kaiser, A.-K., Schadmand-Fischer, S., Galle, P.R., Woerns, M. |
|---|---|
| Zdroj: | In European Journal of Cancer December 2014 50(18):3125-3135 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect